

Ref: FOI/GS/ID 8625

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

17 November 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL).

You asked: All questions are shown as received by the Trust.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- Azacitidine monotherapy*
- Low dose cytarabine (LoDAC) monotherapy*
- Venetoclax + azacitidine*
- Venetoclax + LoDAC*
- Ivosidenib*
- Intensive chemotherapy-based regimen*
- Other*

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

- Azacitidine monotherapy*
- Low dose cytarabine (LoDAC) monotherapy*
- Venetoclax + azacitidine*
- Venetoclax + LoDAC*
- Ivosidenib*
- Intensive chemotherapy-based regimen*
- Other*

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Patients with chronic lymphocytic leukaemia (CLL)

4. *How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?*

5. *How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?*

Trust response:

1. 42

2. 5

3. 13

4. 22

5. 0